Latest News

Bellingham, Washington – In the realm of biomedical sciences, the quest for accurate and efficient diagnostic tools is ever-evolving. One such promising innovation making waves is the photoacoustic (PA) technique. In the past decade, PA imaging has emerged as a viable imaging modality demonstrated in many clinical applications with promising...
SEOUL, South Korea and HYDERABAD, India — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, today announced that it has commenced a technology transfer of simplified Oral Cholera Vaccine (OCV-S) to Biological E. Limited...
Changwon, South Korea – Dr. Min-young Lee and Dr. Sung-gyu Park of the Advanced Bio and Healthcare Materials Research Division at KIMS have developed a technology that can detect cancer mutant genes in blood with the world’s highest sensitivity of 0.000000001% based on plasmonic nanomaterials for optical signal amplification. The...
Reported cases of multi-system inflammatory syndrome (MIS-C) in children and adolescents who had received at least one COVID-19 vaccine dose were rare (estimated at one case per million vaccinated individuals in this age group). The reporting rate for cases without evidence of SARS-CoV-2 infection was 0.3 cases per million vaccinated...
DUBLIN, Ireland — Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy...
PHILADELPHIA – Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the data from the Phase 3 PROPEL pivotal trial, assessing the efficacy, safety and tolerability of AT-GAA in adults with late-onset Pompe disease compared to the standard of...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. — United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full results of its ADVANCE OUTCOMES study, available here. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Ralinepag reduced the risk...